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Abstract - Sexual behavioral and other risk factors and the prevalence of genital human papillomavirus (HPV) infection are 
very important for the monitoring of HPV infection and cervical cancer prevention strategies. The purpose of this study 
was to determine the risk factors, prevalence of cervical HPV infection and genotype distribution among asymptomatic 
young women with normal cytology in Serbia. A total of 204 consenting young women were enrolled in this study and 
interviewed about risk factors. The presence of HPV DNA was assessed using the PCR method. HPV genotypes were 
identified by direct sequencing. Cervical HPV infection was detected in 19.1% of women. Out of nine identified HPV 
genotypes, types 16 and 52 were the most frequent. A significant association was found only between the number of sexual 
partners and HPV positivity (p<0.05). The obtained results showed the high prevalence of high-risk HPV types among 
young women in Serbia. 
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INTRODUCTION
Cervical cancer is the leading cause of cancer mor-
tality among women in Serbia, where the incidence 
of cervical cancer is among the highest in Europe. 
According to the data of the Cancer Registry of Ser-
bia, from 1973-1982 the incidence was 14.7 to 18.2 
per 100.000, while in the year 2002 the age-stand-
ardized incidence rate of cervical cancer was 27.2 per 
100.000. Recent data from 2003-2009 show incidence 
rates from 21.6 to 27.1 per 100.000 (Kesic et al., 2007; 
Cancer Registry of Serbia, 2011).
Throughout the last decades, a strong and causal 
association between HPV and cervical cancer has 
been  demonstrated  and  established  (Bosch  et  al., 
2008). To date, 120 HPV genotypes have been iden-
tified and according to the oncogenic potential, they 
are classified into 2 groups. High-risk genotypes are 
associated with cervical cancer while low risk types 
are associated with genital warts. All genotypes can 
cause an abnormal Pap test (Bernard et al., 2010; 
Clifford et al., 2006). 
Genital HPV infection is one of the most fre-
quent sexually transmitted infections. Usually it is 
without symptoms and in most cases the immune 
system and in particular cellular immunity, clears the 
infection, while in some cases persistent infection is 
established. The establishment of persistent infection 1278 ALEKSANDRA KNEŽEVIĆ ET AL.
is a key point in the development of cervical carci-
noma. The peak incidence of HPV infection occurs 
in adolescents and young women, while cervical can-
cer typically follows 20-30 years later (Baseman and 
Koutsky, 2005; Trottier and Franco, 2006).
Risk  factors  for  genital  HPV  infection  can  be 
classified as factors for HPV acquisition and cofac-
tors for the progression of infection and development 
of cervical cancer. The most important factors for 
HPV acquisition are younger age and sexual behav-
ioral factors such as an earlier age of initiating sexual 
intercourse, the lifetime number of sexual partners 
and the sexual practices of male partners. The most 
important cofactors for the progression are immu-
nosuppression,  other  infectious  agents  (especially 
sexually  transmitted  infectious  agents  like  Herpes 
simplex virus type 2, Chlamydia trachomatis, etc.), 
smoking, parity, oral contraceptives, dietary factors 
and genetics (Trottier and Franco, 2006; Bosch et al., 
2008). Therefore, the determination of sexual behav-
ioral patterns and other risk factors, as well as the 
prevalence and HPV genotype distribution, is very 
important for the defining and monitoring of HPV 
infection and cancer prevention strategies (Bosch et 
al., 2008). 
Based on the epidemiological data that the peak 
incidence of genital HPV infection is in young wom-
en, the aim of this study was to determine the risk 
factors,  prevalence  of  cervical  HPV  infection  and 
genotype distribution among asymptomatic young 
women with normal cytology in Serbia.
MATERIALS AND METHODS
Study population and specimen collection
This study was reviewed and approved by the Ethical 
Committee, Faculty of Medicine, University of Bel-
grade. A total of 204 consenting women aged 19 to 
31 years (mean age 23.08±2.46) attending Gynecol-
ogy Department, University Policlinics in Belgrade, 
were enrolled in this study. Inclusion criteria for the 
women recruited for this study were normal cervical 
cytology and the absence of genital clinical manifes-
tations. Participants were interviewed using a ques-
tionnaire about sexual behavior and lifestyle. 
Cervical cell samples, used for HPV testing, were 
collected with an endocervical brush and placed in 
5 ml of sterile phosphate-buffered saline, refriger-
ated and transported to the laboratory. 
HPV DNA amplification and detection
Samples were centrifuged (3000 g for 10 min) 
and the supernatant was removed. The pellet was 
used for DNA extraction with a QIAamp DNA Mini 
Kit (QIAGEN Inc., CA, USA) according to the man-
ufacturer’s instructions. 
Amplification of HPV DNA was carried out with 
the consensus primer pair MY09/MY11 for the HPV 
L1 gene (Gravitt et al., 2000). PCRs were performed 
in a 25 μL volume reaction mix containing Qiagen 
Taq PCR Master Mix-250U (QIAGEN Inc., Valencia, 
CA, USA), 1 μmol of each primer and 5 μl of extract-
ed DNA. The PCR conditions were as follows: initial 
denaturation at 95˚C for 5 min was followed by 40 
cycles: 30 s at 94˚C, 30 s at 58˚C and 1 min at 72˚C, 
and a final extension of 20 min at 72˚C. The specific 
450 bp band for HPV DNA was detected by agarose 
gel electrophoresis (Gravitt et al., 2000).
HPV genotyping
HPV genotypes were identified by the direct sequenc-
ing method. PCR products were purified with a QIA-
GEN MinElute PCR Purification Kit (QIAGEN Inc., 
Valencia, CA, USA), according to the manufacturer’s 
instructions. The purified PCR products were sub-
sequently sequenced with Big Dye Terminator Cycle 
Sequencing Kit (PE Applied Biosystems, Foster City, 
CA, USA) using PCR primers as sequencing prim-
ers. Sequencing reactions were analyzed on the ABI 
Prism 310 Genetic Analyzer. 
The obtained nucleotide sequences were aligned 
and  compared  with  documented  virus  sequences 
available in the GenBank database using the BLAST 
tool  (http://www.ncbi.nlm.nih.gov/BLAST/).  The CERVICAL HPV INFECTION IN SERBIA 1279
nucleotide sequence was assigned to an HPV type if 
it corresponded in more than 95% in 350-400bp with 
a known HPV genotype (Remmerbach et al., 2004; 
Lee et al., 2007).
Statistical analysis
Statistical analysis was performed with SPSS version 
17.0. using the Chi-square, t test and Man-Whitney 
U test as appropriate. Differences with a p-value of 
<0.05 were considered to be significant.
RESULTS
At the time of enrollment, the female study partici-
pants were on average 23 years old (Table 1). Most 
of them had regular menstrual cycle (93.1%). The 
mean age at first intercourse was 18.8 (range 14-27), 
the average number of partners was 3 (range 1-15) 
and the average age difference of male partners was 
4.5 (range 0-20). Only 21.2% of women enrolled in 
this study always used condoms. Two thirds of the 
interviewed  women  visited  gynecologists  once  or 
Table 1. Features of 204 patients included in this study group 
Risk factors Mean (Range) Std. Deviation No. %
Age                                                          23,08 (19-31) 2,459 - -
    Menstrual cycle
    Irregular - - 14 6.9
         Regular - - 190 93.1
Age of the first intercourse a                      18,88 (14-27) 2,019 - -
No. of lifetime partners b                              3,00 (1-15) 2,338 - -
Age difference of male partner b                   4,52 (0-20) 3,519 - -
Use of condomsc
Always - - 42 21.2
Some use - - 119 60.1
Never - - 37 18.7
Frequency of gynecol. examinationsd
Once or more than once a year - - 171 87.7
Less than once a year - - 24 12.3
No. of pregnanciese
0 - - 176 89.8
1-4 - - 20 10.2
No. of abortionsf
0 - - 180 91.4
1-3 - - 17 8.6
Smokers b - - 64 32.0
a Reported for 199 patients
b Reported for 200 patients
c Reported for 198 patients
d Reported for 195 patients
e Reported for 196 patients
f Reported for 197 patients1280 ALEKSANDRA KNEŽEVIĆ ET AL.
more than once a year. There were 32% of smokers in 
our study group (Table 1). 
Out of the 204 women, HPV DNA was detected 
in 39 (19.1%). The prevalence rates of type-specific 
infections are presented in Fig. 1. Out of 9 identi-
fied HPV genotypes, types 16 and 52 were the most 
frequent (23% and 15.4%, respectively) and together 
accounted for 38.4% of all isolates. This group was 
followed by HPV types 33, 42 and 58, which all ap-
pear with the frequency of 7.7%. All other types were 
detected at frequencies ≤5%. According to the cervi-
cal oncogenicity, high-risk HPV types were detected 
in 64.1% of HPV-positive women. In 25.6% of the 
HPV-positive women, genotypes were not identified 
due to the appearance of numerous ambiguous or 
overlapping peaks in the DNA sequencing tracings, 
indicating  the  possibility  of  the  presence  of  more 
than one HPV genotype.
The evaluation of sexual behavioral risk factors 
showed that the presence of HPV infection was not 
associated with the age at first intercourse or the age 
of the partner (p>0.05) (Table 2). However, signifi-
cant association was found between the number of 
sexual partners and HPV positivity (p<0.05).
The  analysis  of  other  risk  factors  revealed  no 
significant association with HPV positivity (p>0.05) 
(Table 2).
Table 2. The association between risk factors and HPV positivity
Risk factors
HPV positive 
No. of patients
HPV negative 
No. of patients
Statistical analysis
Age at the first intercoursea 38 161
t= -1.250; df=47.76 
p>0.05
No. of lifetime partnersb 38 162
Z=-2.76 
p<0.01*
Age difference of male partnersb 38 162
Z=-1.662
p>0.05
Use of condomsc
Always 5 37
X2=2.588; df=2
p>0.05
Some use 27 92
Never 6 31
No. of pregnanciese
0 35 142 X2=0.000; df=1
p>0.05 1-4 3 16
No. of abortionsf
0 35 145 X2=0.000; df=1
p>0.05 1-3 3 14
Smokers b
Yes 17 47 X2=3.498; df=1
p>0.05 No 21 115
a Reported for 199 patients 
b Reported for 200 patients
c Reported for 198 patients
e Reported for 196 patients
f Reported for 197 patientsCERVICAL HPV INFECTION IN SERBIA 1281
DISCUSSION
The recognition that HPV infection is essential for 
the development of cervical carcinoma has led to the 
introduction of HPV testing in cervical cancer pre-
vention programs. It has been suggested that within 
cervical screening programs, HPV testing could be 
suitable for primary screening in the absence of, or in 
conjunction with cytology, management and triage 
of women with low-grade disease and test of cure of 
treatment of high-grade disease (Cuschieri and Cu-
bie, 2005; Cuzick et al., 2008).
The most sexually active women will be infected 
with one or more genital HPV types at some point 
during their lifetime. The most comprehensive data 
about HPV prevalence are in women with normal 
cytology because the majority of women with any cy-
tological abnormality are known to be HPV positive 
(Baseman and Koutsky, 2005; Bosch et al., 2008). 
The prevalence of cervical HPV infection varies 
greatly  worldwide.  Recent  meta-analytical  studies 
have shown that in Europe the overall prevalence of 
HPV infection in women is 9.7%, while in sub-Saha-
ran Africa it is much higher (22.5%). Furthermore, 
it  has  been  shown  that  the  prevalence  of  HPV  is 
age-dependent, with a peak in young sexually active 
women (<25 and 25-34 years) (Clifford et al., 2005; 
Bruni et al., 2010).
In  this  study,  HPV  prevalence  was  19.1%  in 
young women with normal cervical cytology. This 
result is very similar to HPV prevalence in other 
eastern and southern European countries in a simi-
lar age group and in women with normal cervical 
Fig. 1. Distribution of HPV genotypes1282 ALEKSANDRA KNEŽEVIĆ ET AL.
cytology (WHO/ICO Information Centre on HPV 
and Cervical Cancer, 2010; Bruni et al., 2010).
In  addition,  comprehensive  meta-analysis 
showed differences in the worldwide distribution of 
HPV genotypes, where the most common HPV type 
in either single or multiple infections was HPV16, 
followed by HPV42, HPV58, HPV31, HPV18, HPV 
56, HPV81, HPV35, HPV33, HPV45 and HPV52. 
Type 16 was twice as frequent as any other high-
risk type in all regions except in sub-Saharan Afri-
ca, where HPV35 was equally common. In Europe, 
HPV16 was present in 25.5%, followed by HPV31 
(9%) (Clifford et al., 2006; Bruni et al., 2010).
The distribution of HPV genotypes identified in 
this study population, as well as the prevalence of 
high-risk genotypes (64.1%), is similar to the geno-
type distribution in other European countries, where 
the  most  common  type  is  HPV16  (23%).  How-
ever, the distribution of other high-risk HPV types 
(HPV52, HPV58 and HPV45) is higher in this study 
group compared to other European countries.
Although HPV 18 is reported to be among com-
mon high-risk infections in other countries, this type 
was not detected in our study population. 
It has been suggested that infection with multi-
ple HPV types is associated with an increased risk of 
disease progression. It is not clear if this observation 
is due to differences in host susceptibility, interac-
tion between viruses or the independent probability 
of progression associated with each viral type. The 
prevalence  of  multiple  infections  is  up  to  35%  of 
HPV-positive samples from patients with advanced 
cytological  disorders,  whereas  multiple  genotypes 
are less prevalent in carcinoma patients (Baseman 
and Koutsky, 2005; Molijn et al., 2005).
In our study population, cervical infections with 
more than one HPV type were found in 25.6% of 
HPV-positive women. This result is very similar to 
those of a recent meta-analytical study that showed 
that about 20% of HPV-positive women with normal 
cervical cytology have had infections with multiple 
HPV types (Bruni et al., 2010). 
Numerous risk factors for HPV infections have 
been identified. The determination of sexual behav-
ior patterns is fundamental for understanding HPV 
transmission dynamics (Burchell et al., 2006; Bosch 
et al., 2008). 
Various  epidemiological  studies  have  shown 
that sexual debut usually occurs in the late teens be-
tween 15 and 24 years, usually around the age of 20 
(Burchell et al., 2006; Vaccarella et al., 2006; Bosch 
et al., 2008). In our study, the average age of the first 
intercourse was 18.8, and most of the participants 
had had sexual debut between 17 and 20 years of 
age (74.4%), which is consistent with the data from 
these studies. However, there was no significant as-
sociation between the age at first intercourse and 
HPV positivity.
The most consistent risk factor for HPV acquisi-
tion is an increased number of sexual partners as well 
as the age difference of the male partners (Burchell et 
al., 2006; Vaccarella et al., 2006; Bosch et al., 2008). 
This is supported in this study by the observed sig-
nificant association between HPV positivity and the 
number of sexual partners, however, the presence of 
HPV infection was not associated with the age of the 
partner.
The significant association between HPV posi-
tivity and other risk factors (the use of condoms, 
number of pregnancies and abortions, smoking) are 
not shown in this study.
As a result of increased awareness of the rising 
incidence and mortality of cervical cancer in Ser-
bia and the importance of early detection and treat-
ment of this disease, the Ministry of Health of Serbia 
nominated a National Committee for the Prevention 
of Cervical Cancer to develop and implement a Na-
tional Program for cervical cancer screening with the 
technical support of the World Health Organization 
(Nikula et al., 2009). CERVICAL HPV INFECTION IN SERBIA 1283
The obtained results of HPV prevalence, geno-
type distribution and risk factors for HPV acquisi-
tion, as well as the results of future studies with a 
larger cohort, may contribute to the development of 
a cervical carcinoma prevention program in Serbia.
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